FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial

被引：1
|
作者：
Loupakis, Fotios
Cremolini, Chiara
Masi, Gianluca
Lonardi, Sara
Zagonel, Vittorina
Trenta, Patrizia
Tomasello, Gianluca
Ronzoni, Monica
Ciuffreda, Libero
Zaniboni, Alberto
Tonini, Giuseppe
Buonadonna, Angela
Valsuani, Chiara
Chiara, Silvana
Carlomagno, Chiara
Boni, Corrado
Marcucci, Lorenzo
Boni, Luca
Falcone, Alfredo
机构：
[1] Azienda Osped Univ Pisana, Ist Toscano Tumori, UO Oncol Med 2, Pisa, Italy
[2] Ist Oncol Veneto IRCCS, Padua, Italy
[3] DH Oncol Policlin Umberto I, Rome, Italy
[4] Azienda Istituti Ospitalieri Cremona, Div Med & Oncol Med, Cremona, Italy
[5] Ist Sci San Raffaele, Dipartimento Oncol, Milan, Italy
[6] Molinette Mauriziano Hosp, Med Oncol Unit, Turin, Italy
[7] Casa Cura Poliambulanza, UO Oncol Med, Brescia, Italy
[8] Univ Campus Bio Med, Rome, Italy
[9] Ist Nazl Tumori, Dipartimento Oncol Med, Aviano, Italy
[10] Osped Versilia, UO Oncol Med, Viareggio, Italy
[11] Natl Canc Inst, Medial Oncol Unit, Genoa, Italy
[12] Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy
[13] Arcispedale S Maria Nuova, Div Oncol, Reggio Emilia, Italy
[14] USL 5 Pontedera, Div Med Oncol, Pontedera, Italy
[15] Ist Toscano Tumori, Florence, Italy
[16] Univ Pisa, Dipartimento Oncol Trapianti & Nuove Tecnol Med, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.336
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
336
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.
    Cremolini, Chiara
    Loupakis, Fotios
    Masi, Gianluca
    Zagonel, Vittorina
    Bergamo, Francesca
    Salvatore, Lisa
    Cortesi, Enrico
    Tomasello, Gianluca
    Ronzoni, Monica
    Pinta, Francesco
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Amoroso, Domenico
    Sonaglio, Claudia
    De Stefano, Alfonso
    Boni, Corrado
    Allegrini, Giacomo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.
    Falcone, Alfredo
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Loupakis, Fotios
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
    Cremolini, C.
    Rossini, D.
    Antoniotti, C.
    Pietrantonio, F.
    Lonardi, S.
    Salvatore, L.
    Marmorino, F.
    Borelli, B.
    Ambrosini, M.
    Barsotti, G.
    Di Stefano, B.
    Masi, G.
    Boccaccino, A.
    Tamberi, S.
    Tamburini, E.
    Frassineti, L. G.
    Simionato, F.
    Fontanini, G.
    Boni, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1294 - S1295
  • [4] FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial
    Falcone, A.
    Cremolini, C.
    Loupakis, F.
    Lonardi, S.
    Casagrande, M. E.
    Murgioni, S.
    Salvatore, L.
    Masi, G.
    Fanotto, V.
    Granetto, C.
    Marmorino, F.
    Ginocchi, L.
    Ziampiri, S.
    Grande, R.
    Tonini, G.
    Delfanti, S.
    Di Donato, S.
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] A phase II trial of alternating mXELOX/mXELIRI plus bevacizumab (BEV) as first-line treatment for metastatic colorectal cancer (mCRC)
    Li, Sheng
    Zhu, Liangjun
    Li, Xiaoyou
    Huang, Jiayuan
    Xu, Hanfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC).
    Tatli, Ali Murat
    Coskun, Hasan Senol
    Uysal, Mukremin
    Goksu, Sema Sezgin
    Arslan, Deniz
    Gunduz, Seyda
    Ozdogan, Mustafa
    Bozcuk, Hakan Sat
    Savas, Burhan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Bergamo, Francesca
    Gallano, Antonella
    Zagonel, Vittorina
    Ferrari, Laura
    Ongaro, Elena
    Cardellino, Giovanni
    Marcucci, Lorenzo
    Lucchesi, Sara
    Banzi, Maria
    Ciarlo, Andrea
    Miraglio, Emanuele
    Delfanti, Sara
    Corsi, Domenico C.
    Zaniboni, Alberto
    Tonlni, Giuseppe
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [9] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Clemens Giessen
    Ludwig Fischer von Weikersthal
    Axel Hinke
    Sebastian Stintzing
    Frank Kullmann
    Ursula Vehling-Kaiser
    Julia Mayerle
    Markus Bangerter
    Claudio Denzlinger
    Markus Sieber
    Christian Teschendorf
    Jens Freiberg-Richter
    Christoph Schulz
    Dominik Paul Modest
    Nicolas Moosmann
    Philipp Aubele
    Volker Heinemann
    BMC Cancer, 11
  • [10] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Giessen, Clemens
    von Weikersthal, Ludwig Fischer
    Hinke, Axel
    Stintzing, Sebastian
    Kullmann, Frank
    Vehling-Kaiser, Ursula
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Freiberg-Richter, Jens
    Schulz, Christoph
    Modest, Dominik Paul
    Moosmann, Nicolas
    Aubele, Philipp
    Heinemann, Volker
    BMC CANCER, 2011, 11
12345